Breaking the oral barrier（2）

IL-23 competitive pattern (peptides&small molecules)

At present, numerous articles have explored the competitive landscape of IL-23 antibodies, and this article will focus on the research and development progress of peptides and small molecules. In the development of oral drugs targeting IL-23/IL-23R, the cyclic peptide inhibitor PN-235 (Icotrokinra, JNJ-2113) developed by Johnson&Johnson and Protagonist has made the fastest progress. It has completed key clinical trials in the treatment of psoriasis and submitted a marketing application to the FDA, demonstrating significant clinical efficacy and good application prospects. However, there is still significant room for optimization in the in vivo PK of PN-235 molecule. According to publicly available patent information, Hisilicon submitted a priority patent for IL-23R cyclic peptide inhibitor in 2023 (published in November 2024), and its clinical HSK47388 may be derived from this patent, intended for the treatment of psoriasis and inflammatory bowel disease. According to the information in the Medical Magic Cube database, Sanofi and Hausen are also actively laying out their plans. Their developed cyclic peptide inhibitors are based on PN-235 and are currently in the preclinical research stage. Lingke Pharmaceutical has also listed IL-23 in its pipeline, which is currently in the drug discovery stage. According to the Wisdom Bud database information, it is a small molecule drug. Nimble Therapeutics, Mopac Biologics, and Morphic Therapeutics also use oral small molecules or peptides targeting IL-23R/IL23 as early development pipelines on their official websites, but no relevant information has been made public yet.